Needham: Maintaining the DoCGO (DCGO.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $10.00 to $7.00.
DocGo Analyst Ratings
Cantor Fitzgerald Maintains Overweight on DocGo, Lowers Price Target to $5
Deutsche Bank Adjusts DocGo Price Target to $5 From $8.20, Maintains Buy Rating
DocGo (DCGO) Has a New Rating From Northland Securities
Analysts Are Bullish on Top Healthcare Stocks: DocGo (DCGO), Avadel Pharmaceuticals (AVDL)
Buy Rating on DocGo: Strong Growth Potential and Financial Health Despite Revenue Base Changes
DocGo Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), DocGo (DCGO) and Revvity (RVTY)
DocGo Analyst Ratings
Stifel: Maintaining the DocGO (DCGO.US) rating, adjusted from buy to buy rating, and adjusted the target price from $11.00 to $8.00.
DocGo Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)
Deutsche Bank Cuts DocGo Price Target to $8.20 From $10, Maintains Buy Rating
DocGo Analyst Ratings
Needham Maintains Buy on DocGo, Lowers Price Target to $10
Northland Securities Sticks to Their Buy Rating for DocGo (DCGO)
Stifel Nicolaus Remains a Buy on DocGo (DCGO)
Buy Rating Affirmed for DocGo: Strong FY23 Finish and Promising FY24 Outlook Fuel Growth Prospects
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC)